The cancer planning solution serves as an essential component to monitoring concordance with evidence-based guidelines and yearly quality improvement initiatives.
Atlanta, GA (Jan 20, 2022):
The Commission on Cancer (CoC) accredits approximately 1,500 cancer centers nationwide. Continuous quality improvement activities are critical to maintaining this accreditation and driving advancements in cancer care quality. Within this landscape, OncoLens has emerged as an essential platform for cross-discipline data sharing and analyses that lead to better care decisions, patient outcomes, and CoC quality improvement compliance.
As part of the CoC accreditation process, cancer programs must perform quality improvement initiatives aimed at “problem resolution, outcomes improvement, and assurances of patient safety (Commission on Cancer, 2020).” Cancer programs are required to foster a collaborative culture that empowers participants to analyze and implement improvements to care quality. This includes [Quality Standard 7.2] monitoring concordance with evidence-based guidelines and [Quality Standard 7.3] executing at least one yearly cancer-specific quality improvement initiative.
CoC accreditation is designed to encourage hospitals, treatment centers, and other facilities to improve the quality of care across the entire cancer continuum, including prevention, survivorship, and end-of-life care. While 2020 Standard revisions lowered the number of cases reviewed and quality studies performed to meet quality improvement requirements, ensuring compliance and maintaining collaboration remain challenging. Quality improvement demands multidisciplinary inputs and a centralized hub for data sharing, information, and analysis. With disjointed technology stacks, disparate data, and few options to streamline communications, cancer programs struggle to drive the multidisciplinary collaboration that underpins the CoC’s standards.
OncoLens, a holistic platform supporting the entire cancer patient journey, is helping cancer centers drive collaborative engagement and unlock data to support quality standards. Recent projects have improved the identification of advanced Non-Small Cell Lung Cancer (NSCLC) patients eligible for frontline-immune checkpoint inhibition therapy using biomarker test results. This included baselining current practices and identifying barriers leading to variation within a facility.
“Cancer programs are using OncoLens to perform in-depth analyses that determine if diagnosis and initial treatment are concordant with evidence-based national treatment guidelines. In addition, the collaborative capabilities native to the platform are facilitating quality improvement initiatives by aggregating data, supporting problem statement development, and driving the monitoring and measurement of quality improvement program activities,” said Anju Mathew, OncoLens chief executive officer.
Planned activities across 2022 will continue to support cancer centers already live on the OncoLens platform, deliver non-OncoLens programs the opportunity to participate in sponsored quality improvement initiatives, and provide insights to the CoC on additional measures and benchmarks indicative of multidisciplinary care quality and improved patient outcomes.